VEGFR2 inhibitors, including sorafenib, sunitinib, pazopanib, lenvatinib, vandetanib, and cabozantinib, have been approved for use by the FDA in treating different types of cancers such as thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.7,8 However, these drugs have limitations such as resistance and side effects, necessitating the identification of newer, more effective scaffolds with fewer side effects. This evidence concerns the gene KDR and cancer.